SynapDx Licenses Gene Expression Technology from Children's Hospital Boston | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup SynapDx said today it has licensed technology from Children's Hospital Boston for the development of blood-based tests for the early detection of autism spectrum disorders.

Citing statistics from the Centers for Disease Control, SynapDx said about one in every 110 children in the US has the disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.